Skip to main content
PMC home page
Cancer Immunology, Immunotherapy : CII logoLink to Cancer Immunology, Immunotherapy : CII
. 1991 Mar;34(2):111–114. doi: 10.1007/BF01741344

Interleukin-2 dose, blood monocyte and CD25+ lymphocyte counts as predictors of clinical response to interleukin-2 therapy in patients with renal cell carcinoma

Gregers G Hermann 1,✉, Poul F Geertsen 2, Hans von der Maase 2, Jesper Zeuthen 1
PMCID: PMC11038133  PMID: 1760814

Abstract

The purpose of this study was to determine immunological parameters in the peripheral blood that correlate with the clinical effect of interleukin-2 (IL-2) in patients with metastatic renal cell cancer. A group of 26 patients with metastatic renal cell cancer underwent IL-2 treatment using a 36-day schedule with continuous intravenous IL-2 infusion (3 × 106 units m−2 day−1) administered from days 1 to 5 and days 12 to 16. The white blood cell count and the absolute and relative number of neutrophils, lymphocytes, eosinophils and monocytes were recorded six times in peripheral blood during the treatment. Also the blood counts of T cell and NK cell subsets and cells expressing the T cell activation markers IL-2Rα and VLA-1 were measured. The lymphokine-activated killer (LAK) cell cytotoxicity was measured either with or without additional in vitro stimulation by IL-2. Multivariate statistical analysis showed that the clinical responses were related to the administered dose of IL-2, to a low number of blood cells expressing IL-2 receptors and to a reduction in the blood monocyte count (P <0.05).

Key words: Renal cell carcinoma, IL-2, Response prediction, CD25+ lymphocytes

References

  • 1.Afifi AA, Clark V. Computer aided multivariable analysis. Belmont. Calif.: Lifetime Learning Publications; 1984. [Google Scholar]
  • 2.Boldt DH, Mills BJ, Gemlo BT, Holden H, Mier J, Paietta E, McMannis JD, Escobedo LV, Sniecinski I, Rayner AA, Hawkins MJ, Atkins MB, Ciobanu N, Ellis TM. Laboratory correlates of adoptive immunotherapy with recombinant interleukin-2 and lymphokine-activated killer cells in humans. Cancer Res. 1988;48:4409. [PubMed] [Google Scholar]
  • 3.Böyum A. Isolation of leucocytes from human blood. Scand J Clin Lab Invest. 1968;21:77. [PubMed] [Google Scholar]
  • 4.Bubenik J, Baresova M, Viklicky V, Jakoubkova J, Sainerova H, Donner J. Established cell line of urinary bladder carcinoma (T24) containing tumour-specific antigen. Int J Cancer. 1973;11:765. doi: 10.1002/ijc.2910110327. [DOI] [PubMed] [Google Scholar]
  • 5.Christensen B, Kieler J, Vilien M, Don P, Wang CY, Wolf H. A classification of human urothelial cells propagated in vitro. Anticancer Res. 1984;4:319. [PubMed] [Google Scholar]
  • 6.Cohen PJ, Lotze MT, Roberts JR, Rosenberg SA, Jaffe ES. The immunopathology of sequential tumor biopsies in patients treated with interleukin-2. Correlation of response with T-cell infiltration and HLA-DR expression. Am J Pathol. 1987;129:208. [PMC free article] [PubMed] [Google Scholar]
  • 7.Dimitriu-Bona A, Burmester GR, Waters SJ, Winchester RJ. Human mononuclear phagocyte differentiation antigens: I. Patterns of antigenic expression on the surface of human monocytes and macrophages defined by monoclonal antibodies. J Immunol. 1983;130:145. [PubMed] [Google Scholar]
  • 8.Ettinghausen SE, Moore JG, White DE, Plantanias L, Young NS, Rosenberg SA. Hematologic effects of immunotherapy with lymphokine-activated killer cells and recombinant interleukin-2 in cancer patients. Blood. 1987;69:1654. [PubMed] [Google Scholar]
  • 9.Favrot MC, Combaret V, Negrier S, Philip I, Thiesse P, Freydel C, Bijmann JT, Franks CR, Mercatello A, Philip T. Functional and immunophenotypic modifications induced by IL-2 did not predict response to therapy in patients with renal cell carcinoma. J Biol Response Mod. 1990;9:167. [PubMed] [Google Scholar]
  • 10.Hank JA, Weil-Hillman G, Surfus JE, Sosman JA, Sondel PM. Addition of interleukin-2 in vitro augments detection of lymphokine-activated killer activity generated in vivo. Cancer Immunol Immunother. 1990;31:53. doi: 10.1007/BF01742496. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11.Hemler ME. VLA proteins in the integrin family: Structures, functions, and their role on leukocytes. Annu Rev Immunol. 1990;8:365. doi: 10.1146/annurev.iy.08.040190.002053. [DOI] [PubMed] [Google Scholar]
  • 12.Hemler ME, Jacobson JG, Brenner MB, Mann D, Strominger JL. VLA-1: A T cell surface antigen which defines a novel late stage of human T cell activation. Eur J Immunol. 1986;15:502. doi: 10.1002/eji.1830150515. [DOI] [PubMed] [Google Scholar]
  • 13.Hermann GG, Petersen KR, Steven K, Zeuthen J. Reduced LAK-cytotoxicity of peripheral blood mononuclear cells in patients with bladder cancer: Decreased LAK-cytotoxicity caused by a low incidence of CD56+ and CD57+ mononuclear blood cells. J Clin Immunol. 1990;10:311. doi: 10.1007/BF00917476. [DOI] [PubMed] [Google Scholar]
  • 14.Hermann GG, Zeuthen J, Claësson MH (1991) LAK cell mediated cytotoxicity against tumor cell targets used to monitor the stimulatory effect of interleukin-2: Cytotoxicity, target recognition and phenotype of effector cells lysing the Daudi, T24 and K562 tumor cell lines. Nat Immun Cell Growth Regul (in press) [PubMed]
  • 15.Krigel RL, Padavic-Schaller KA, Rudolph AR, Konrad M, Bradley EC, Comis RL. Renal cell carcinoma: Treatment with recombinant interleukin-2 plus beta interferon. J Clin Oncol. 1990;8:460. doi: 10.1200/JCO.1990.8.3.460. [DOI] [PubMed] [Google Scholar]
  • 16.Miller AB, Hogstraten B, Staquet M, Winkler A. Reporting results of cancer treatment. Cancer. 1981;47:207. doi: 10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6. [DOI] [PubMed] [Google Scholar]
  • 17.Mitchel MS, Kempf RA, Harel W, Shau H, Boswell WD, Lind S, Bradley EC. Effectiveness and tolerability of low-dose cyclophosphamide and low dose intravenous interleukin-2 in disseminated melanoma. J Clin Oncol. 1988;6:409. doi: 10.1200/JCO.1988.6.3.409. [DOI] [PubMed] [Google Scholar]
  • 18.Rosenberg SA, Mulé JJ, Spiess PJ, Reichert CM, Schwarz SL. Regression of established pulmonary metastases and subcutaneous tumors mediated by the systemic administration of high-dose recombinant interleukin-2. J Exp Med. 1985;161:1169. doi: 10.1084/jem.161.5.1169. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 19.Rosenberg SA, Lotze MT, Yang JC, Aebersold PM, Linehan WM, Seipp CA, White DE. Experience with the use of high-dose interleukin-2 in the treatment of 652 cancer patients. Ann Surg. 1989;210:474. doi: 10.1097/00000658-198910000-00008. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Rubin JT, Elwood LJ, Rosenberg SA, Lotze MT. Immunohistochemical correlates of response to recombinant interleukin-2-based immunotherapy in humans. Cancer Res. 1989;49:7086. [PubMed] [Google Scholar]
  • 21.Vilien M, Wolf H, Rasmussen F. Follow-up investigations of bladder cancer patients by titration of natural and specific lymphocyte-mediated cytotoxicity. Cancer Immunol Immunother. 1981;10:171. [Google Scholar]
  • 22.West WH, Tauer KW, Yannelli JR, Marshall GD, Orr DW, Thurman GB, Oldham RK. Constant-infusion recombinant interleukin-2 in adoptive immunotherapy of advanced cancer. N Engl J Med. 1987;316:898. doi: 10.1056/NEJM198704093161502. [DOI] [PubMed] [Google Scholar]

Articles from Cancer Immunology, Immunotherapy : CII are provided here courtesy of Springer

RESOURCES